WCWanyi Chen

Wanyi Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wanyi Chen has a total of 58 co-authors. Here are the top co-authors by number of shared publications:

  • Min Zhang

    Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing, China

    6 shared publications
  • Xiaoxiao Wang

    Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing, China

    6 shared publications
  • Tiantian Tang

    Department of Pharmacy, Chongqing University Cancer Hospital, No.181 Hanyu Road, Shapingba District, Chongqing 400030, PR China

    5 shared publications
  • Lixian Li

    Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing 400030, China

    4 shared publications
  • Qiaoqiao Li

    Department of Pharmacy, Chongqing University Cancer Hospital, No.181 Hanyu Road, Shapingba District, Chongqing 400030, PR China

    4 shared publications
  • Siyu Li

    Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing, China

    4 shared publications

Latest Publications

  • Open Access

    X‐ray‐Activated Asymmetric Cobalt Single‐Atom Nanozyme Potentiates Catalytic Immunotherapy via Enhanced Peroxidase‐Like Activity

    by Bo Chen, Xuelin Tao, Yu Wang, Xiaoxiao Wang, Yongzhong Wu, Wanyi Chen

    Single‐atom nanozymes (SAzymes) have emerged as promising platforms for catalytic therapy owing to their atomic precision and tunable electronic structures. Here, we report an asymmetrically coordinated cobalt SAzyme featuring Co‐N 3 C active sites anchored within a hafnium‐based metal–organic framework (Hf‐MOF). The engineered HfCoNC nanozyme exhibits significantly enhanced peroxidase‐like activity and enables efficient X‐ray–activated catalytic immunotherapy. The asymmetric Co‐N 3 C coordination optimizes substrate adsorption and lowers the reaction energy barrier, thereby accelerating the catalytic reaction. In the tumor microenvironment, HfCoNC efficiently converts endogenous H 2 O 2 into highly cytotoxic hydroxyl radicals (•OH), while low‐dose X‐ray irradiation further amplifies reactive oxygen species (ROS) production. The resulting oxidative stress induces extensive DNA damage and activates the cGAS‐STING signaling pathway. Moreover, the release of Co 2+ ions, together with the co‐delivered STING agonist, further potentiates systemic antitumor immunity, effectively suppressing tumor growth and metastasis. This work provides a promising strategy for developing SAzyme‐based platforms for synergistic catalytic radioimmunotherapy.

  • From tumor microenvironment orchestrators to actionable targets: a systematic review of TAM-targeted therapies in triple-negative breast cancer

    by Yuxin Pei, Jiao Zhang, Chao Li, Yuanqiang Wang, Qinghua Yu, Wanyi Chen

    Background Triple-negative breast cancer (TNBC) is an aggressive subtype lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, with limited treatment options. Tumor-associated macrophages (TAMs), as key immune cells in the tumor microenvironment, exacerbate the malignancy of TNBC by promoting angiogenesis, metastasis, immune evasion, and drug resistance. Method We systematically searched PubMed, Web of Science, and ClinicalTrials.gov databases to collect clinical trials targeting TAMs for the treatment of TNBC. Data from completed and ongoing studies were extracted and analyzed, focusing on strategies that inhibit macrophage recruitment, clearance, and reprogramming, as well as their combination with standard therapies. Results TAMs in TNBC predominantly exhibit an M2-like pro-tumor phenotype, originating from circulating monocytes and tissue-resident macrophages, and drive progression through multiple pathways. Clinical trials indicate preliminary efficacy for strategies including CSF-1/CSF-1R inhibitors, bisphosphonates, and reprogramming agents—particularly when combined with chemotherapy or immune checkpoint inhibitors—though response rates vary, and optimal regimens remain under investigation. Conclusion TAMs represent a promising therapeutic target in TNBC. Emerging clinical evidence supports the potential of targeted therapies against them, though further optimization of patient selection and combination strategies is required. This review provides a systematic foundation for advancing treatments targeting TAMs. We confirm that the scientific content remains unchanged.


  • Open Access

    Physiologically Based Pharmacokinetic Modeling to Assess Antiretroviral–BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Regimens

    by Lu Chen, Xiaoxiao Wang, Lixian Li, Yi Yang, Yao Liu, Wanyi Chen

    Objectives: The co-administration of Bruton’s tyrosine kinase (BTK) inhibitors with antiretroviral drugs is challenging due to potential drug–drug interactions (DDIs). However, clinical trials specifically assessing such DDIs are lacking. We aimed to evaluate DDIs between the BTK inhibitors ibrutinib, zanubrutinib and acalabrutinib with representative antiretroviral drugs and to provide dose adjustment strategies using physiologically based pharmacokinetic (PBPK) models. Methods: PBPK models were developed in PK-Sim software. Model performance was verified by comparing simulated pharmacokinetic parameters and DDI magnitudes with probe drugs (midazolam or maraviroc) with reported clinical data. The validated models were subsequently applied to assess DDIs and explore dose adjustment strategies. Results: The developed PBPK model accurately describes the pharmacokinetics of each drug. Darunavir/ritonavir substantially increased the maximum plasma concentration (Cmax) of ibrutinib, zanubrutinib, and acalabrutinib by 496%, 312%, and 160%, respectively. In contrast, efavirenz reduced Cmax by 43%, 33%, and 37%, respectively, while etravirine caused smaller decreases of 5%, 0%, and 10%. Based on these predictions, recommended dose adjustment strategies include ibrutinib 105 mg once daily, zanubrutinib 40 mg twice daily, and acalabrutinib 50 mg twice daily when co-administered with darunavir/ritonavir or ibrutinib 980 mg once daily, zanubrutinib 240 mg twice daily, and acalabrutinib 150 mg twice daily when co-administered with efavirenz. No dose adjustment is required with etravirine. Conclusions: The PBPK models accurately predicted the in vivo pharmacokinetics of ibrutinib, zanubrutinib, acalabrutinib, and those of the antiretrovirals darunavir/ritonavir, efavirenz, and etravirine, and the DDIs between them. The dose adjustment strategies provided information valuable to the optimization of antineoplastic therapy in HIV-related lymphoma (HRL) patients.

  • Open Access

    A pharmacovigilance study of thromboembolism events associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors based on FAERS database

    by Zongwei Tang, Haichi Song, Lingyun Pan, Min Zhang, Siyu Li, Wenrui Li, Wanyi Chen, Xiaoxiao Wang

    Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) represent a class of targeted drugs that have changed the cancer therapy landscape. However, the anti-angiogenic effect of VEGFR-TKIs significantly increase the incidence of cardiovascular adverse events (AEs). In this study, we conducted a comprehensive analysis of VEGFR-TKI-related thromboembolic events (TEEs), using data from the FAERS database between the drug launch and the third quarter of 2023. Disproportionality analysis, including reporting odds ratio, proportional reporting ratio, bayesian confidence propagation neural network, and multi-item gamma poisson shrinker, were used to explore the correlation between VEGFR-TKIs and TEEs. The total number of reported TEEs was 2688, representing 2.98% of all AEs associated with VEGFR-TKIs. A total of 17 and 12 preferred terms of arterial and venous thromboembolic events were observed in 8 VEGFR-TKIs. Lenvatinib, a VEGFR-TKI with low selectivity and high potency, exhibited the strongest TEE signal. A tendency of an increased signal of disproportionate reporting of TEEs was observed in sorafenib, regorafenib, and sunitinib. Indication, gender, age, drug class, concomitant medication and AEs may influence the occurrence of VEGFR-TKI-related TEEs. This study illustrates that TEEs are highly associated with VEGFR-TKIs, emphasizing the importance of screening for the TEE risks during VEGFR-TKI therapy.


  • Switching-Type Fluorescence Probe Based on Carbon Dot Nanocomposites for the Visual Detection of Superoxide Anions

    by Jiao Zhang, Bin Liao, Yuxin Pei, Yuxin Huang, Zhiyan Liu, Yuanqiang Wang, Qinghua Yu, Wanyi Chen

    Superoxide anion (O₂⁻), as a crucial member of reactive oxygen species (ROS), plays a pivotal role in cellular function regulation within biological systems and has been extensively implicated in the pathogenesis and progression of numerous diseases. In this paper, we successfully prepare a switching fluorescent probe (O-QD@Ag) for visual monitoring of superoxide anion (O₂⁻) by coating silver nanolayer on the surface of carbon quantum dots (CQDs). The experimental results show that the fluorescence signal of the composite is quenched in the presence of silver nanolayers. A good linear relationship between the fluorescence intensity of the probe and the O₂⁻ concentration is observed within the range of 0.2–2 µM, with a calculated detection limit (LOD) of 190 nM (LOD=\(\:\frac{3{\upsigma\:}}{\text{S}}\)). This demonstrates the probe’s capability for sensitive and quantitative detection of O₂⁻ in biological systems. In addition, O-QD@Ag composite exhibits excellent biocompatibility and low toxicity, which is characterized by low toxicity in normal MCF-10 A and MDA-MB-436 cancer cells, and is suitable for selective detection of intracellular O₂⁻. To sum up, the probe not only provides an effective means to monitor the pathological process of chronic diseases such as cancer, cardiovascular diseases and neurodegenerative diseases but also shows the potential value of application in disease prognosis evaluation.


  • Open Access

    Prevention and treatment of anthracycline-induced cardiotoxicity: a systematic review and network meta-analysis of randomized controlled trials

    by Siyu Li, Wenrui Li, Mengfei Cheng, Xiaoxiao Wang, Wanyi Chen

    Background: Anthracyclines are cornerstone chemotherapeutics, but cardiotoxicity limits their use. Objective: This study aims to evaluate the efficacy of various drugs in preventing and treating anthracycline-induced cardiotoxicity (AIC). Methods: We conducted an extensive search across seven databases to identify randomized controlled trials (RCTs) pertinent to the prevention and treatment of AIC with medications. Subsequently, a Bayesian Model-based network meta-analysis was performed in the R 4.4.0. Results: A total of 128 RCTs involving 10,431 cancer patients treated with anthracyclines and 78 drug regimens were included in this study. The network meta-analysis results showed that, compared with patients who did not receive cardioprotective drugs, those treated with Calcium Dibutyryladenosine Cyclophosphate (Mean Difference [95% Credible Interval], 8.760 [0.5917, 16.92]), Carvedilol (4.024 [0.5372, 7.656]), Carvedilol + Candesartan (7.934 [3.159, 12.91]), Compound Salvia Miltiorrhiza + Levocarnitine (9.087 [0.9160, 17.25]), Dexrazoxane (5.066 [2.589, 7.540]), Dexrazoxane + Cinobufacini (11.61 [4.590, 18.70]), Dexrazoxane + Shenqi Fuzheng (13.05 [4.640, 21.40]), Nicorandil (14.24 [5.122, 23.31]), Qiliqiangxin (11.38 [2.826, 19.91]), and Xinmai Long (6.371 [1.735, 11.02]) experienced less decrease in LVEF after chemotherapy. The SUCRA ranking results indicated that the most effective treatment option for preserving LVEF was Nicorandil (SUCRA 91.76%). Conclusion: Apart from Dexrazoxane, Carvedilol, a β-blocker, also appears to show significant potential in preventing AIC. Furthermore, our results indicate that there is insufficient evidence to support the beneficial effects of statins, Sildenafil, Ivabradine, Levocarnitine, N-acetylcysteine, Glutathione, Coenzyme Q10, Vitamin E, and Vitamin C in preventing LVEF decline and exerting a positive effect on the prevention of AIC.


  • Open Access

    Progress and current trends in prediction models for the occurrence and prognosis of cancer and cancer-related complications: a bibliometric and visualization analysis

    by Siyu Li, Wenrui Li, Xiaoxiao Wang, Wanyi Chen

    Objective: Prediction models, which estimate disease or outcome probabilities, are widely used in cancer research. This study aims to identify hotspots and future directions of cancer-related prediction models using bibliometrics.Methods: A comprehensive literature search was conducted in the Science Citation Index Expanded (SCIE) from the Web of Science Core Collection (WoSCC) up to November 15, 2024, focusing on cancer-related prediction models research. Co-occurrence analyses of countries, institutions, authors, journals, and keywords were conducted using VOSviewer 1.6.20. Additionally, keyword clustering, timeline visualization, and burst term analysis were performed with CiteSpace 6.3.Results: A total of 1,661 records were retrieved from the SCIE. After deduplication and eligibility screening, 1,556 publications were included in the analysis. The bibliometric analysis revealed a consistent annual increase in cancer-related prediction model research, with China and the United States emerging as the leading contributors. The United States, England, and the Netherlands had the strongest collaborative networks. The most frequent keywords, excluding “prediction model” and “predictive model”, included nomogram (frequency=192), survival (191), risk (121), prognosis (112), breast cancer (103), carcinoma (93), validation (87), surgery (85), diagnosis (83), chemotherapy (80), and machine learning (77). Besides, the timeline view analysis indicated that the “#7 machine learning” cluster was experiencing vigorous growth.Conclusion: Cancer-related prediction models are rapidly advancing, especially in prognostic models. Emerging modeling techniques, such as neural networks and deep learning algorithms, are likely to play a pivotal role in current and future cancer-related prediction model research. Systematic reviews of cancer-related predictive models, which could help clinicians select the optimal model for specific clinical conditions may emerge as potential research directions in this field.

  • Open Access

    Potential interactions between traditional Chinese medicine and osimertinib: a Case Report

    by Min Zhang, Huiwen Ma, Wanyi Chen, Zhongzhen Yuan

    Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, played a crucial role in the treatment of EGFR-mutated non-small cell lung cancer. This case firstly reported a case of drug-drug interaction between traditional Chinese medicine (TCM) and osimertinib. A 57-year-old female was diagnosed with stage IV lung adenocarcinoma, who switched from gefitinib to osimertinib after disease progression. However, the carcinoembryonic antigen (CEA) results suggested biochemical recurrence after 48 months. The first osimertinib trough concentration (Ctrough) was 82.1 ng/mL, significantly lower than the FDA-reported 166 ng/mL, with concurrent elevation of the tumor marker carcinoembryonic antigen (CEA). After excluding other possible factors, the decreased osimertinib concentration might be due to the TCM taken by the patient. After adjusting the TCM prescription, the patient’s osimertinib Ctrough was stable within the range of 145 and 228 ng/mL without significant adverse reactions and carcinoembryonic antigen levels stabilized. This case underscored the importance of monitoring drug concentrations in patients concurrently using TCM and osimertinib to optimize treatment outcomes and minimize potential drug-drug interactions.


  • High BMI predicts poor cancer pain relief when rotating from oral opioids to transdermal Fentanyl: a two-center retrospective study

    by Ya Chen, Songling Han, Xiaogang Hu, Xue Ma, Yue Qiu, Yuelu Tang, Xiaoxiao Wang, Lixian Li, Chao Li, Wanyi Chen

    Background The analgesic effect of transdermal fentanyl (TDF) differs among cancer pain patients. This study aims to investigate the relationship between clinical factors and pain relief when using TDF in cancer pain patients who rotate from oral opioids to TDF. Methods A two-center retrospective study was conducted in Chongqing University Cancer Hospital and Sichuan Cancer Hospital, including adult cancer pain patients who rotated from oral opioids to TDF between 2018 and 2022. Based on the clinical characteristics, logistic regressions and directed acyclic graphs (DAG) were employed to identify significant factors influencing the efficacy of TDF. The study adhered to STROBE guidelines. Results This survey included 359 patients, among them, 254 patients (70.8%) attained good pain relief after rotating to TDF. 59.3% of patients utilized TDF at standard dosage, while 24.8% used underdose TDF, with only 52.8% achieving adequate pain relief, significantly lower than other groups (p < 0.001). Initial univariable analysis of 22 clinical factors among the standard dose group showed that a higher body mass index (BMI, median 23.2 kg/m² vs. 21.0 kg/m², OR = 0.83 [0.75–0.91], p < 0.001) and the presence of lung cancer (OR = 0.31 [0.11–0.89], p = 0.030) predicted potentially unsatisfactory pain control after TDF treatment. Subsequently, a multivariable regression analysis based on DAG-directed factor selection identified BMI (OR = 0.82 [0.74–0.92], adjusted p < 0.01) as the only independent factor influencing TDF effectiveness. Conclusions Our study suggested that high BMI was a significant predictor of poor cancer pain relief when rotating from oral opioids to TDF, and provides a useful measurement of managing adult cancer pain when using TDF. Trial registration ClinicalTrials.gov, NCT06369961, registered on April 11, 2024; https://clinicaltrials.gov/study/NCT06369961.